PTH and chronic kidney disease: Since patients with advanced CKD are inherently at high cardiovascular risk, PTH analogs, which have demonstrated a favorable cardiovascular safety profile, represent a reasonable alternative to romosozumab [79] as an anabolic therapy in individuals at very high risk of fracture.